{"protocolSection":{"identificationModule":{"nctId":"NCT03850444","orgStudyIdInfo":{"id":"3475-042 China Extension"},"secondaryIdInfos":[{"id":"152877","type":"OTHER","domain":"JAPIC-CTI"},{"id":"MK-3475-042","type":"OTHER","domain":"Merck"},{"id":"KEYNOTE-042","type":"OTHER","domain":"Merck"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study","officialTitle":"A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)"},"statusModule":{"statusVerifiedDate":"2023-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-08-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-09-04","type":"ACTUAL"},"completionDateStruct":{"date":"2022-09-08","type":"ACTUAL"},"studyFirstSubmitDate":"2019-02-20","studyFirstSubmitQcDate":"2019-02-20","studyFirstPostDateStruct":{"date":"2019-02-21","type":"ACTUAL"},"resultsFirstSubmitDate":"2019-08-05","resultsFirstSubmitQcDate":"2019-08-05","resultsFirstPostDateStruct":{"date":"2019-08-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-08-22","lastUpdatePostDateStruct":{"date":"2023-09-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"In the China extension study, Chinese participants with programmed cell death ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) will be randomized to receive single agent pembrolizumab for up to 35 treatments or standard of care (SOC) platinum-based chemotherapy (carboplatin + paclitaxel or carboplatin + pemetrexed for 4 to 6 21-day cycles). Chinese participants in the platinum-based chemotherapy arms with non-squamous tumor histologies may receive pemetrexed maintenance therapy after the 4 to 6 cycles of chemotherapy. The primary extension study hypothesis is that pembrolizumab prolongs overall survival (OS) compared to SOC chemotherapy in Chinese participants.","detailedDescription":"The China extension study enrolled 262 participants. Of the 262 total participants enrolled, 92 were also previously enrolled in the global study for MK-3475-042 (NCT02220894)."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"],"keywords":["Programmed Cell Death 1 (PD1, PD-1)","Programmed Cell Death 1 Ligand 1 (PDL 1, PD-L1)","Programmed Cell Death 1 Ligand 2 (PDL 2, PD-L2)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":262,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Pembrolizumab","type":"EXPERIMENTAL","description":"Participants receive pembrolizumab 200 mg by IV infusion on Day 1 every 3 weeks (Q3W) for a maximum of 35 cycles (21-day cycles). Participants who stop the initial course of pembrolizumab due to complete response or complete the initial course of pembrolizumab and have stable disease, but progress after discontinuation, are eligible for a second course of pembrolizumab for up to an additional 1 year (17 additional 21-day cycles).","interventionNames":["Biological: pembrolizumab"]},{"label":"SOC Treatment","type":"ACTIVE_COMPARATOR","description":"Participants receive carboplatin at target dose Area Under the Curve (AUC 5) (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies receive optional additional maintenance treatment with pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W.","interventionNames":["Drug: carboplatin","Drug: paclitaxel","Drug: pemetrexed"]}],"interventions":[{"type":"BIOLOGICAL","name":"pembrolizumab","armGroupLabels":["Pembrolizumab"],"otherNames":["MK-3475","KEYTRUDA®"]},{"type":"DRUG","name":"carboplatin","armGroupLabels":["SOC Treatment"],"otherNames":["PARAPLATIN®"]},{"type":"DRUG","name":"paclitaxel","armGroupLabels":["SOC Treatment"],"otherNames":["TAXOL®"]},{"type":"DRUG","name":"pemetrexed","armGroupLabels":["SOC Treatment"],"otherNames":["ALIMTA®"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥50%","description":"OS was determined for participants with a TPS of ≥50% and was defined as the time from randomization until death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. The OS for participants with a TPS ≥50% is presented.","timeFrame":"Up to 23.2 months"},{"measure":"Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥20%","description":"OS was determined for participants with a TPS of ≥20% and was defined as the time from randomization until death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. The OS for participants with a TPS ≥20% is presented.","timeFrame":"Up to 23.2 months"},{"measure":"Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥1%","description":"OS was determined for participants with a TPS of ≥1% and was defined as the time from randomization until death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. The OS for participants with a TPS ≥1% is presented.","timeFrame":"Up to 23.2 months"}],"secondaryOutcomes":[{"measure":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50%","description":"PFS was determined for participants with a TPS of ≥50% and was defined as the time from randomization until the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions or progression in non-target lesions was also considered PD. The PFS per RECIST 1.1 was calculated using the product-limit (Kaplan-Meier) method for censored data. The PFS for participants with a TPS ≥50% is presented.","timeFrame":"Up to 23.2 months"},{"measure":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20%","description":"PFS was determined for participants with a TPS of ≥20% and was defined as the time from randomization until the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions or progression in non-target lesions was also considered PD. The PFS per RECIST 1.1 was calculated using the product-limit (Kaplan-Meier) method for censored data. The PFS for participants with a TPS ≥20% is presented.","timeFrame":"Up to 23.2 months"},{"measure":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1%","description":"PFS was determined for participants with a TPS of ≥1% and was defined as the time from randomization until the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions or progression in non-target lesions was also considered PD. The PFS per RECIST 1.1 was calculated using the product-limit (Kaplan-Meier) method for censored data. The PFS for participants with a TPS ≥1% is presented.","timeFrame":"Up to 23.2 months"},{"measure":"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50%","description":"ORR was determined for participants with a TPS of ≥50%. ORR was determined per RECIST 1.1 and was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target and non-target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1. The percentage of participants who had a TPS ≥50% and who experienced a CR or PR is presented.","timeFrame":"Up to 23.2 months"},{"measure":"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20%","description":"ORR was determined for participants with a TPS of ≥20%. ORR was determined per RECIST 1.1 and was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target and non-target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1. The percentage of participants who had a TPS ≥20% and who experienced a CR or PR is presented.","timeFrame":"Up to 23.2 months"},{"measure":"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1%","description":"ORR was determined for participants with a TPS of ≥1%. ORR was determined per RECIST 1.1 and was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target and non-target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1. The percentage of participants who had a TPS ≥1% and who experienced a CR or PR is presented.","timeFrame":"Up to 23.2 months"},{"measure":"Number of Participants Who Experienced At Least One Adverse Event (AE)","description":"An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. The number of participants who experienced at least one AE is presented.","timeFrame":"Up to 59.7 months"},{"measure":"Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)","description":"An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. The number of participants who discontinued study treatment due to an AE is presented.","timeFrame":"Up to 56.7 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Histologically- or cytologically-confirmed diagnosis of advanced or metastatic NSCLC\n* PD-L1 positive tumor\n* Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\n* Life expectancy of at least 3 months\n* No prior systemic chemotherapy for the treatment of the participant's advanced or metastatic disease (treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as completed at least 6 months prior to diagnosis of advanced or metastatic disease)\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Adequate organ function\n* No prior malignancy, with the exception of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, or in situ cancer, or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy\n* Submission of formalin-fixed diagnostic tumor tissue (in the case of participants having received adjuvant systemic therapy, the tissue should be taken after completion of this therapy)\n* Female participants of childbearing potential must have a negative urine or serum pregnancy test and must be willing to use two adequate barrier methods of contraception or a barrier method plus a hormonal method starting with the screening visit through 120 days after the last dose of pembrolizumab or 180 days after the last dose of chemotherapeutic agents used in the study\n* Male participants with a female partner(s) of childbearing potential must be willing to use two adequate barrier methods of contraception from screening through 120 days after the last dose of pembrolizumab or 180 days after the last dose of chemotherapeutic agents used in the study\n\nExclusion criteria:\n\n* Epidermal growth factor receptor (EGFR)-sensitizing mutation and/or is echinoderm microtubule-associated protein-like 4 (EML4) gene/anaplastic lymphoma kinase (ALK) gene fusion positive\n* Currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of study therapy\n* No tumor specimen evaluable for PD-L1 expression by the central study laboratory\n* Squamous histology and received carboplatin in combination with paclitaxel in the adjuvant setting\n* Is receiving systemic steroid therapy ≤3 days prior to the first dose of study therapy or receiving any other form of immunosuppressive medication with the exception of daily steroid replacement therapy\n* The NSCLC can be treated with curative intent with either surgical resection and/or chemoradiation\n* Expected to require any other form of systemic or localized antineoplastic therapy while on study\n* Any prior systemic cytotoxic chemotherapy, biological therapy or major surgery within 3 weeks of the first dose of study therapy; received lung radiation therapy \\>30 Gy within 6 months of the first dose of study therapy\n* Prior therapy with an anti-PD-1, anti-PD-L1, anti-PDL2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)\n* Known central nervous system metastases and/or carcinomatous meningitis\n* Active autoimmune disease that has required systemic treatment in the past 2 years\n* Had allogeneic tissue/solid organ transplantation\n* Interstitial lung disease or history of pneumonitis that has required oral or IV steroids\n* Has received or will receive a live vaccine within 30 days prior to the first study therapy (seasonal flu vaccines that do not contain live vaccine are permitted)\n* Active infection requiring intravenous systemic therapy\n* Known history of human immunodeficiency virus (HIV)\n* Known active Hepatitis B or C\n* Regular user (including \"recreational use\") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol)\n* Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}]},"referencesModule":{"references":[{"pmid":"33231285","type":"RESULT","citation":"Wu YL, Zhang L, Fan Y, Zhou J, Zhang L, Zhou Q, Li W, Hu C, Chen G, Zhang X, Zhou C, Dang T, Sadowski S, Kush DA, Zhou Y, Li B, Mok T. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study. Int J Cancer. 2021 May 1;148(9):2313-2320. doi: 10.1002/ijc.33399. Epub 2020 Dec 9."}],"seeAlsoLinks":[{"label":"Merck Clinical Trials Information","url":"https://www.merckclinicaltrials.com"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf","url":"http://engagezone.msd.com/ds_documentation.php"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"The China extension study enrolled 262 participants. Of the 262 total participants enrolled, 92 were previously enrolled in the global study for MK-3475-042 (NCT02220894).","groups":[{"id":"FG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 every 3 weeks (Q3W) for a maximum of 35 cycles (21-day cycles). Participants who stopped the initial course of pembrolizumab due to complete response or had completed the initial course of pembrolizumab and had stable disease, but progressed after discontinuation, were eligible for a second course of pembrolizumab for up to an additional 1 year (17 additional 21-day cycles)."},{"id":"FG001","title":"Chemotherapy (SOC Treatment)","description":"Participants received carboplatin at target dose Area Under the Curve (AUC 5) (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies received optional additional maintenance treatment with pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"128"},{"groupId":"FG001","numSubjects":"134"}]},{"type":"Treated","achievements":[{"groupId":"FG000","numSubjects":"128"},{"groupId":"FG001","numSubjects":"125"}]},{"type":"Received Second Course of Pembrolizumab","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"128"},{"groupId":"FG001","numSubjects":"134"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"10"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"87"},{"groupId":"FG001","numSubjects":"107"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"Participation in study terminated by Sponsor","reasons":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"11"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized participants","groups":[{"id":"BG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 every 3 weeks (Q3W) for a maximum of 35 cycles (21-day cycles). Participants who stopped the initial course of pembrolizumab due to complete response or had completed the initial course of pembrolizumab and had stable disease, but progressed after discontinuation, were eligible for a second course of pembrolizumab for up to an additional 1 year (17 additional 21-day cycles)."},{"id":"BG001","title":"Chemotherapy (SOC Treatment)","description":"Participants received carboplatin at target dose Area Under the Curve (AUC 5) (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies received optional additional maintenance treatment with pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"128"},{"groupId":"BG001","value":"134"},{"groupId":"BG002","value":"262"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60.9","spread":"8.1"},{"groupId":"BG001","value":"61.5","spread":"8.0"},{"groupId":"BG002","value":"61.2","spread":"8.1"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"38"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"105"},{"groupId":"BG001","value":"119"},{"groupId":"BG002","value":"224"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"128"},{"groupId":"BG001","value":"134"},{"groupId":"BG002","value":"262"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"128"},{"groupId":"BG001","value":"134"},{"groupId":"BG002","value":"262"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)","description":"Participants were assessed for ECOG PS: Grade 0: Fully active, able to carry on all pre-disease performance without restriction; Grade 1: Restricted in physically strenuous activity but ambulatory \\& able to carry out work of a light or sedentary nature; Grade 2: Ambulatory \\& capable of all selfcare but unable to carry out any work activities, up \\& about more than 50% of waking hours; Grade 3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; Grade 4: Completely disabled, cannot carry on any selfcare, totally confined to bed or chair or Grade 5: Dead.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"ECOG PS=0","categories":[{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"60"}]}]},{"title":"ECOG PS=1","categories":[{"measurements":[{"groupId":"BG000","value":"97"},{"groupId":"BG001","value":"105"},{"groupId":"BG002","value":"202"}]}]}]},{"title":"Programmed Cell Death-Ligand 1 (PD-L1) Tumor Expression Status","description":"Participants were assessed for their PD-L1 tumor expression status by immunohistochemistry assay using tumor tissue from an archival or newly obtained biopsy. Participants with a tumor proportion score (TPS) were classified as follows: ≥50% = PD-L1 strongly positive; 1-49% = PD-L1 weakly positive; and \\<1% = PD-L1 negative.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"TPS=≥50%","categories":[{"measurements":[{"groupId":"BG000","value":"72"},{"groupId":"BG001","value":"74"},{"groupId":"BG002","value":"146"}]}]},{"title":"TPS=20-49%","categories":[{"measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"58"}]}]},{"title":"TPS=1-19%","categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"58"}]}]},{"title":"TPS=<1%","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Tumor Histology","description":"Participants were classified according to tumor histology: Squamous or Non-squamous. The tumor histology determined potential treatment regimen.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Squamous","categories":[{"measurements":[{"groupId":"BG000","value":"71"},{"groupId":"BG001","value":"76"},{"groupId":"BG002","value":"147"}]}]},{"title":"Non-squamous","categories":[{"measurements":[{"groupId":"BG000","value":"57"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"115"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥50%","description":"OS was determined for participants with a TPS of ≥50% and was defined as the time from randomization until death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. The OS for participants with a TPS ≥50% is presented.","populationDescription":"The analysis population included all participants who were alive at the time of randomization and had a TPS of ≥50%.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to 23.2 months","groups":[{"id":"OG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 every 3 weeks (Q3W) for a maximum of 35 cycles (21-day cycles). Participants who stopped the initial course of pembrolizumab due to complete response or had completed the initial course of pembrolizumab and had stable disease, but progressed after discontinuation, were eligible for a second course of pembrolizumab for up to an additional 1 year (17 additional 21-day cycles)."},{"id":"OG001","title":"Chemotherapy (SOC Treatment)","description":"Participants received carboplatin at target dose Area Under the Curve (AUC 5) (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies received optional additional maintenance treatment with pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"74"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","lowerLimit":"15.5","upperLimit":"NA","comment":"NA = upper limit not reached at time of data cut-off due to insufficient number of participants with an event."},{"groupId":"OG001","value":"14.0","lowerLimit":"10.0","upperLimit":"17.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.62","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.38","ciUpperLimit":"1.00","estimateComment":"Hazard ratio based on Cox regression model with treatment as a covariate stratified by ECOG PS (0 vs. 1), and histology (squamous vs. non-squamous)."}]},{"type":"PRIMARY","title":"Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥20%","description":"OS was determined for participants with a TPS of ≥20% and was defined as the time from randomization until death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. The OS for participants with a TPS ≥20% is presented.","populationDescription":"The analysis population included all participants who were alive at the time of randomization and had a TPS of ≥20%.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to 23.2 months","groups":[{"id":"OG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 every 3 weeks (Q3W) for a maximum of 35 cycles (21-day cycles). Participants who stopped the initial course of pembrolizumab due to complete response or had completed the initial course of pembrolizumab and had stable disease, but progressed after discontinuation, were eligible for a second course of pembrolizumab for up to an additional 1 year (17 additional 21-day cycles)."},{"id":"OG001","title":"Chemotherapy (SOC Treatment)","description":"Participants received carboplatin at target dose Area Under the Curve (AUC 5) (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies received optional additional maintenance treatment with pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"103"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","lowerLimit":"17.4","upperLimit":"NA","comment":"NA = upper limit not reached at time of data cut-off due to insufficient number of participants with an event."},{"groupId":"OG001","value":"13.7","lowerLimit":"10.1","upperLimit":"17.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.62","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.41","ciUpperLimit":"0.95","estimateComment":"Hazard ratio based on Cox regression model with treatment as a covariate stratified by ECOG PS (0 vs. 1), PD-L1 expression status (TPS=≥50% vs. TPS=1-49%), and histology (squamous vs. non-squamous)."}]},{"type":"PRIMARY","title":"Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥1%","description":"OS was determined for participants with a TPS of ≥1% and was defined as the time from randomization until death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. The OS for participants with a TPS ≥1% is presented.","populationDescription":"The analysis population included all participants who were alive at the time of randomization and had a TPS of ≥1%.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to 23.2 months","groups":[{"id":"OG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 every 3 weeks (Q3W) for a maximum of 35 cycles (21-day cycles). Participants who stopped the initial course of pembrolizumab due to complete response or had completed the initial course of pembrolizumab and had stable disease, but progressed after discontinuation, were eligible for a second course of pembrolizumab for up to an additional 1 year (17 additional 21-day cycles)."},{"id":"OG001","title":"Chemotherapy (SOC Treatment)","description":"Participants received carboplatin at target dose Area Under the Curve (AUC 5) (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies received optional additional maintenance treatment with pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"134"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","lowerLimit":"17.4","upperLimit":"NA","comment":"NA = upper limit not reached at time of data cut-off due to insufficient number of participants with an event."},{"groupId":"OG001","value":"13.7","lowerLimit":"10.1","upperLimit":"17.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.65","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.45","ciUpperLimit":"0.94","estimateComment":"Hazard ratio based on Cox regression model with treatment as a covariate stratified by ECOG PS (0 vs. 1), PD-L1 expression status (TPS=≥50% vs. TPS=1-49%), and histology (squamous vs. non-squamous)."}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50%","description":"PFS was determined for participants with a TPS of ≥50% and was defined as the time from randomization until the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions or progression in non-target lesions was also considered PD. The PFS per RECIST 1.1 was calculated using the product-limit (Kaplan-Meier) method for censored data. The PFS for participants with a TPS ≥50% is presented.","populationDescription":"The analysis population included all participants who were alive at the time of randomization and had a TPS of ≥50%.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to 23.2 months","groups":[{"id":"OG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 every 3 weeks (Q3W) for a maximum of 35 cycles (21-day cycles). Participants who stopped the initial course of pembrolizumab due to complete response or had completed the initial course of pembrolizumab and had stable disease, but progressed after discontinuation, were eligible for a second course of pembrolizumab for up to an additional 1 year (17 additional 21-day cycles)."},{"id":"OG001","title":"Chemotherapy (SOC Treatment)","description":"Participants received carboplatin at target dose Area Under the Curve (AUC 5) (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies received optional additional maintenance treatment with pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"74"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","lowerLimit":"4.2","upperLimit":"10.6"},{"groupId":"OG001","value":"6.5","lowerLimit":"4.4","upperLimit":"9.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.85","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.57","ciUpperLimit":"1.28","estimateComment":"Hazard ratio based on Cox regression model with treatment as a covariate stratified by ECOG PS (0 vs. 1), and histology (squamous vs. non-squamous)."}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20%","description":"PFS was determined for participants with a TPS of ≥20% and was defined as the time from randomization until the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions or progression in non-target lesions was also considered PD. The PFS per RECIST 1.1 was calculated using the product-limit (Kaplan-Meier) method for censored data. The PFS for participants with a TPS ≥20% is presented.","populationDescription":"The analysis population included all participants who were alive at the time of randomization and had a TPS of ≥20%.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to 23.2 months","groups":[{"id":"OG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 every 3 weeks (Q3W) for a maximum of 35 cycles (21-day cycles). Participants who stopped the initial course of pembrolizumab due to complete response or had completed the initial course of pembrolizumab and had stable disease, but progressed after discontinuation, were eligible for a second course of pembrolizumab for up to an additional 1 year (17 additional 21-day cycles)."},{"id":"OG001","title":"Chemotherapy (SOC Treatment)","description":"Participants received carboplatin at target dose Area Under the Curve (AUC 5) (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies received optional additional maintenance treatment with pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"103"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"4.2","upperLimit":"8.4"},{"groupId":"OG001","value":"6.5","lowerLimit":"5.9","upperLimit":"8.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.99","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.70","ciUpperLimit":"1.39","estimateComment":"Hazard ratio based on Cox regression model with treatment as a covariate stratified by ECOG PS (0 vs. 1), PD-L1 expression status (TPS=≥50% vs. TPS=1-49%), and histology (squamous vs. non-squamous)."}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1%","description":"PFS was determined for participants with a TPS of ≥1% and was defined as the time from randomization until the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions or progression in non-target lesions was also considered PD. The PFS per RECIST 1.1 was calculated using the product-limit (Kaplan-Meier) method for censored data. The PFS for participants with a TPS ≥1% is presented.","populationDescription":"The analysis population included all participants who were alive at the time of randomization and had a TPS of ≥1%.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to 23.2 months","groups":[{"id":"OG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 every 3 weeks (Q3W) for a maximum of 35 cycles (21-day cycles). Participants who stopped the initial course of pembrolizumab due to complete response or had completed the initial course of pembrolizumab and had stable disease, but progressed after discontinuation, were eligible for a second course of pembrolizumab for up to an additional 1 year (17 additional 21-day cycles)."},{"id":"OG001","title":"Chemotherapy (SOC Treatment)","description":"Participants received carboplatin at target dose Area Under the Curve (AUC 5) (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies received optional additional maintenance treatment with pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"134"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"4.2","upperLimit":"8.3"},{"groupId":"OG001","value":"6.4","lowerLimit":"5.9","upperLimit":"7.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Hazard Ratio (HR)","paramValue":"1.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.74","ciUpperLimit":"1.35","estimateComment":"Hazard ratio based on Cox regression model with treatment as a covariate stratified by ECOG PS (0 vs. 1), PD-L1 expression status (TPS=≥50% vs. TPS=1-49%), and histology (squamous vs. non-squamous)."}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50%","description":"ORR was determined for participants with a TPS of ≥50%. ORR was determined per RECIST 1.1 and was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target and non-target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1. The percentage of participants who had a TPS ≥50% and who experienced a CR or PR is presented.","populationDescription":"The analysis population included all participants who were alive at the time of randomization and had a TPS of ≥50%.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Up to 23.2 months","groups":[{"id":"OG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 every 3 weeks (Q3W) for a maximum of 35 cycles (21-day cycles). Participants who stopped the initial course of pembrolizumab due to complete response or had completed the initial course of pembrolizumab and had stable disease, but progressed after discontinuation, were eligible for a second course of pembrolizumab for up to an additional 1 year (17 additional 21-day cycles)."},{"id":"OG001","title":"Chemotherapy (SOC Treatment)","description":"Participants received carboplatin at target dose Area Under the Curve (AUC 5) (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies received optional additional maintenance treatment with pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"74"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.7","lowerLimit":"30.2","upperLimit":"53.9"},{"groupId":"OG001","value":"24.3","lowerLimit":"15.1","upperLimit":"35.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Stratified Miettinen and Nurminen","paramType":"Difference in Percentage (DP)","paramValue":"17.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.8","ciUpperLimit":"31.6","estimateComment":"DP for pembrolizumab vs. chemotherapy based on Miettinen \\& Nurminen method stratified by ECOG PS (0 vs. 1) and histology (squamous vs. non-squamous)."}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20%","description":"ORR was determined for participants with a TPS of ≥20%. ORR was determined per RECIST 1.1 and was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target and non-target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1. The percentage of participants who had a TPS ≥20% and who experienced a CR or PR is presented.","populationDescription":"The analysis population included all participants who were alive at the time of randomization and had a TPS of ≥20%.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Up to 23.2 months","groups":[{"id":"OG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 every 3 weeks (Q3W) for a maximum of 35 cycles (21-day cycles). Participants who stopped the initial course of pembrolizumab due to complete response or had completed the initial course of pembrolizumab and had stable disease, but progressed after discontinuation, were eligible for a second course of pembrolizumab for up to an additional 1 year (17 additional 21-day cycles)."},{"id":"OG001","title":"Chemotherapy (SOC Treatment)","description":"Participants received carboplatin at target dose Area Under the Curve (AUC 5) (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies received optional additional maintenance treatment with pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"103"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.6","lowerLimit":"26.4","upperLimit":"45.8"},{"groupId":"OG001","value":"24.3","lowerLimit":"16.4","upperLimit":"33.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Difference in Percentage (DP)","paramValue":"11.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.4","ciUpperLimit":"23.7","estimateComment":"DP for pembrolizumab vs. chemotherapy based on Miettinen \\& Nurminen method stratified by ECOG PS (0 vs. 1), PD-L1 expression status (TPS=≥50% vs. TPS=1-49%), and histology (squamous vs. non-squamous)."}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1%","description":"ORR was determined for participants with a TPS of ≥1%. ORR was determined per RECIST 1.1 and was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target and non-target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1. The percentage of participants who had a TPS ≥1% and who experienced a CR or PR is presented.","populationDescription":"The analysis population included all participants who were alive at the time of randomization and had a TPS of ≥1%.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Up to 23.2 months","groups":[{"id":"OG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 every 3 weeks (Q3W) for a maximum of 35 cycles (21-day cycles). Participants who stopped the initial course of pembrolizumab due to complete response or had completed the initial course of pembrolizumab and had stable disease, but progressed after discontinuation, were eligible for a second course of pembrolizumab for up to an additional 1 year (17 additional 21-day cycles)."},{"id":"OG001","title":"Chemotherapy (SOC Treatment)","description":"Participants received carboplatin at target dose Area Under the Curve (AUC 5) (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies received optional additional maintenance treatment with pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"134"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.8","lowerLimit":"24.8","upperLimit":"41.7"},{"groupId":"OG001","value":"24.6","lowerLimit":"17.6","upperLimit":"32.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Difference in Percentage (DP)","paramValue":"8.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.0","ciUpperLimit":"18.9","estimateComment":"DP for pembrolizumab vs. chemotherapy based on Miettinen \\& Nurminen method stratified by ECOG PS (0 vs. 1), PD-L1 expression status (TPS=≥50% vs. TPS=1-49%), and histology (squamous vs. non-squamous)."}]},{"type":"SECONDARY","title":"Number of Participants Who Experienced At Least One Adverse Event (AE)","description":"An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. The number of participants who experienced at least one AE is presented.","populationDescription":"The analysis population consisted of all participants who received ≥1 dose of study treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 59.7 months","groups":[{"id":"OG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 every 3 weeks (Q3W) for a maximum of 35 cycles (21-day cycles). Participants who stopped the initial course of pembrolizumab due to complete response or had completed the initial course of pembrolizumab and had stable disease, but progressed after discontinuation, were eligible for a second course of pembrolizumab for up to an additional 1 year (17 additional 21-day cycles)."},{"id":"OG001","title":"Chemotherapy (SOC Treatment)","description":"Participants received carboplatin at target dose Area Under the Curve (AUC 5) (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies received optional additional maintenance treatment with pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"125"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"124"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)","description":"An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. The number of participants who discontinued study treatment due to an AE is presented.","populationDescription":"The analysis population consisted of all participants who received ≥1 dose of study treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 56.7 months","groups":[{"id":"OG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 every 3 weeks (Q3W) for a maximum of 35 cycles (21-day cycles). Participants who stopped the initial course of pembrolizumab due to complete response or had completed the initial course of pembrolizumab and had stable disease, but progressed after discontinuation, were eligible for a second course of pembrolizumab for up to an additional 1 year (17 additional 21-day cycles)."},{"id":"OG001","title":"Chemotherapy (SOC Treatment)","description":"Participants received carboplatin at target dose Area Under the Curve (AUC 5) (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies received optional additional maintenance treatment with pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"125"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"22"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to 70.4 months","description":"All-cause mortality=all randomized participants. Adverse events (AEs)=all participants who received ≥1 dose of treatment. Per protocol, disease progression was not considered an AE unless related to treatment. Medical Dictionary for Regulatory Activities (MedDRA) terms neoplasm progression, malignant neoplasm progression, and disease progression not related to treatment were excluded.","eventGroups":[{"id":"EG000","title":"Pembrolizumab","description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 every 3 weeks (Q3W) for a maximum of 35 cycles (21-day cycles). Participants who stopped the initial course of pembrolizumab due to complete response or had completed the initial course of pembrolizumab and had stable disease, but progressed after discontinuation, were eligible for a second course of pembrolizumab for up to an additional 1 year (17 additional 21-day cycles).","deathsNumAffected":99,"deathsNumAtRisk":128,"seriousNumAffected":42,"seriousNumAtRisk":128,"otherNumAffected":119,"otherNumAtRisk":128},{"id":"EG001","title":"Chemotherapy (SOC Treatment)","description":"Participants received carboplatin at target dose Area Under the Curve (AUC 5) (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies received optional additional maintenance treatment with pemetrexed 500 mg/m\\^2 by IV infusion on Day 1 Q3W.","deathsNumAffected":117,"deathsNumAtRisk":134,"seriousNumAffected":41,"seriousNumAtRisk":125,"otherNumAffected":119,"otherNumAtRisk":125},{"id":"EG002","title":"Pembrolizumab Second Course","description":"Participants who met the criteria for a second course of pembrolizumab received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle for up to an additional 1 year (17 additional 21-day cycles) of treatment.","deathsNumAffected":4,"deathsNumAtRisk":5,"seriousNumAffected":2,"seriousNumAtRisk":5,"otherNumAffected":5,"otherNumAtRisk":5}],"seriousEvents":[{"term":"Agranulocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Coagulopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Acute left ventricular failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Arteriosclerosis coronary artery","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Ischaemic cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Lower gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Multiple organ dysfunction syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Autoimmune hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Hepatitis E","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Lymph gland infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":5}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":128},{"groupId":"EG001","numEvents":13,"numAffected":11,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Pulmonary tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Craniocerebral injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Protein urine present","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Electrolyte imbalance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":128},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":5}]},{"term":"Ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Joint range of motion decreased","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Malignant neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Metastases to bone","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Oesophageal carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Haemorrhage intracranial","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"VIth nerve disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Acute interstitial pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":128},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Drug eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":39,"numAtRisk":128},{"groupId":"EG001","numEvents":116,"numAffected":72,"numAtRisk":125},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":5}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":128},{"groupId":"EG001","numEvents":46,"numAffected":16,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Lymphadenitis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":5}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":27,"numAffected":15,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":10,"numAffected":7,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":15,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":5}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":128},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":128},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":17,"numAtRisk":128},{"groupId":"EG001","numEvents":37,"numAffected":30,"numAtRisk":125},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":5}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":8,"numAtRisk":128},{"groupId":"EG001","numEvents":15,"numAffected":13,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":10,"numAtRisk":128},{"groupId":"EG001","numEvents":36,"numAffected":24,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":128},{"groupId":"EG001","numEvents":23,"numAffected":18,"numAtRisk":125},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":5}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":128},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":128},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":128},{"groupId":"EG001","numEvents":16,"numAffected":15,"numAtRisk":125},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":5}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":10,"numAtRisk":128},{"groupId":"EG001","numEvents":38,"numAffected":20,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":128},{"groupId":"EG001","numEvents":19,"numAffected":18,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":29,"numAtRisk":128},{"groupId":"EG001","numEvents":24,"numAffected":23,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":15,"numAtRisk":128},{"groupId":"EG001","numEvents":8,"numAffected":4,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":10,"numAtRisk":128},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":19,"numAtRisk":128},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":47,"numAffected":28,"numAtRisk":128},{"groupId":"EG001","numEvents":55,"numAffected":31,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":27,"numAtRisk":128},{"groupId":"EG001","numEvents":44,"numAffected":26,"numAtRisk":125},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":5}]},{"term":"Bilirubin conjugated increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":10,"numAtRisk":128},{"groupId":"EG001","numEvents":9,"numAffected":4,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Blood albumin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":128},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":13,"numAtRisk":128},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Blood thyroid stimulating hormone increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":128},{"groupId":"EG001","numEvents":9,"numAffected":4,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Blood urea increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":128},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Blood uric acid increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":14,"numAtRisk":128},{"groupId":"EG001","numEvents":25,"numAffected":11,"numAtRisk":125},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":5}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":128},{"groupId":"EG001","numEvents":232,"numAffected":69,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":5,"numAtRisk":128},{"groupId":"EG001","numEvents":87,"numAffected":29,"numAtRisk":125},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":5}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":18,"numAtRisk":128},{"groupId":"EG001","numEvents":19,"numAffected":15,"numAtRisk":125},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":5}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":128},{"groupId":"EG001","numEvents":241,"numAffected":64,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":24,"numAtRisk":128},{"groupId":"EG001","numEvents":66,"numAffected":38,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":13,"numAtRisk":128},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":125},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":5}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":12,"numAtRisk":128},{"groupId":"EG001","numEvents":21,"numAffected":6,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":17,"numAtRisk":128},{"groupId":"EG001","numEvents":28,"numAffected":19,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":11,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":18,"numAtRisk":128},{"groupId":"EG001","numEvents":16,"numAffected":11,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":17,"numAtRisk":128},{"groupId":"EG001","numEvents":18,"numAffected":13,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Hypoproteinaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":12,"numAtRisk":128},{"groupId":"EG001","numEvents":19,"numAffected":11,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":23,"numAtRisk":128},{"groupId":"EG001","numEvents":25,"numAffected":15,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":12,"numAtRisk":128},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":128},{"groupId":"EG001","numEvents":13,"numAffected":9,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":128},{"groupId":"EG001","numEvents":16,"numAffected":13,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":128},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":128},{"groupId":"EG001","numEvents":13,"numAffected":11,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":14,"numAtRisk":128},{"groupId":"EG001","numEvents":25,"numAffected":14,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":30,"numAtRisk":128},{"groupId":"EG001","numEvents":19,"numAffected":19,"numAtRisk":125},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":5}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":14,"numAtRisk":128},{"groupId":"EG001","numEvents":17,"numAffected":17,"numAtRisk":125},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":5}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":21,"numAtRisk":128},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":125},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":5}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":8,"numAtRisk":128},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":33,"numAffected":32,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":17,"numAtRisk":128},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":23,"numAtRisk":128},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":5,"numAtRisk":128},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":125},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":5}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme LLC","email":"ClinicalTrialsDisclosure@merck.com","phone":"1-800-672-6372"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2021-03-24","uploadDate":"2023-08-22T16:01","filename":"Prot_SAP_001.pdf","size":3767745}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"C565324","term":"Parkinson Disease 4, Autosomal Dominant Lewy Body"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C582435","term":"pembrolizumab"},{"id":"D016190","term":"Carboplatin"},{"id":"D017239","term":"Paclitaxel"},{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}